MedifastMED
MED
About: Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
Employees: 634
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
120% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $5.04M
11% less funds holding
Funds holding: 157 [Q2] → 140 (-17) [Q3]
14.68% less ownership
Funds ownership: 98.44% [Q2] → 83.76% (-14.68%) [Q3]
25% less capital invested
Capital invested by funds: $235M [Q2] → $175M (-$59.6M) [Q3]
41% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 41
46% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 54
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$17
0%
upside
Avg. target
$17
0%
upside
High target
$17
0%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
DA Davidson Linda Bolton Weiser 41% 1-year accuracy 42 / 102 met price target | 0%upside $17 | Neutral Upgraded | 5 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessar.
Positive
Zacks Investment Research
1 month ago
How Should You Play Medifast Stock at a P/E Multiple of 17.6X?
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing MEDIFAST (MED) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Seeking Alpha
1 month ago
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Medifast reported better-than-expected quarterly EPS and is investing in new marketing strategies, AI technologies, and supply chain optimization to drive future growth. Despite a decline in the number of coaches and productivity, MED trades close to its book value and continues to generate free cash flow. The company's stock repurchase plan and significant cash reserves indicate confidence in future growth, with a potential valuation target of $78 per share.
Negative
Zacks Investment Research
1 month ago
MED Q3 Earnings Beat, Revenues Fall on Customer Acquisition Challenges
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.
Positive
Zacks Investment Research
1 month ago
Medifast (MED) Beats Q3 Earnings and Revenue Estimates
Medifast (MED) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $2.12 per share a year ago.
Neutral
Seeking Alpha
1 month ago
Medifast, Inc. (MED) Q3 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call.
Neutral
Business Wire
1 month ago
Medifast Announces Third Quarter 2024 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted.
Neutral
Zacks Investment Research
1 month ago
Medifast Gears Up for Q3 Earnings: Here's What You Should Know
MED's Q3 results may reflect customer acquisition challenges and a decline in active earning OPTAVIA Coaches due to the increasing adoption of GLP-1 medications.
Neutral
Business Wire
1 month ago
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2024
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Offi.
Charts implemented using Lightweight Charts™